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Background. The immunopathogenesis of tuberculosis-associated immune reconstitution inﬂammatory syn-
drome (IRIS) remains incompletely understood, and we know of only 1 disease site-speciﬁc study of the underlying
immunology; we recently showed thatMycobacterium tuberculosis culture positivity and increased neutrophils in the
cerebrospinal ﬂuid (CSF) of patients with tuberculous meningitis (TBM) are associated with TBM-IRIS. In this study
we investigated inﬂammatory mediators at the disease site in patients with TBM-IRIS.
Methods. We performed lumbar puncture at 3–5 time points in human immunodeﬁciency virus (HIV)–infected
patients with TBM (n = 34), including at TBM diagnosis, at initiation of antiretroviral therapy (ART) (day 14), 14 days
after ART initiation, at presentation of TBM-IRIS, and 14 days thereafter. We determined the concentrations of 40
mediators in CSF (33 paired with blood) with Luminex or enzyme-linked immunosorbent assays. Findings were
compared between patients who developed TBM-IRIS (n = 16) and those who did not (TBM-non-IRIS; n = 18).
Results. At TBM diagnosis and 2 weeks after ART initiation, TBM-IRIS was associated with severe, compart-
mentalized inﬂammation in the CSF, with elevated concentrations of cytokines, chemokines, neutrophil-associated
mediators, and matrix metalloproteinases, compared with TBM-non-IRIS. Patients with TBM-non-IRIS whose CSF
cultures were positive for M. tuberculosis at TBM diagnosis (n = 6) showed inﬂammatory responses similar to those
seen in patients with TBM-IRIS at both time points. However, at 2 weeks after ART initiation, S100A8/A9 was sig-
niﬁcantly increased in patients with TBM-IRIS, compared with patients with TBM-non-IRIS whose cultures were
positive at baseline.
Conclusions. A high baseline M. tuberculosis antigen load drives an inﬂammatory response that manifests clin-
ically as TBM-IRIS in most, but not all, patients with TBM. Neutrophils and their mediators, especially S100A8/A9,
are closely associated with the central nervous system inﬂammation that characterizes TBM-IRIS.
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Because of the rapid scale-up of antiretroviral therapy
(ART) programs, tuberculosis-associated immune re-
constitution inﬂammatory syndrome (TB-IRIS) is a sig-
niﬁcant contributor to the healthcare burden in high
TB/HIV coinfection settings [1–3]. Paradoxical TB-
IRIS presents as clinical deterioration after the initiation
of ART in patients who have improved or stabilized
with tuberculosis treatment before ART initiation [4].
This deterioration occurs in the context of a rapid res-
toration of Mycobacterium tuberculosis–speciﬁc im-
mune responses. Neurological TB-IRIS is the most
severe form of TB-IRIS, with an associated mortality
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of 13%–75% [3, 5–7], compared with the 3.2% estimate for all
forms of paradoxical TB-IRIS combined [8].
Although recent studies have advanced understanding of
TB-IRIS through the identiﬁcation of several cellular, immuno-
logical, and genetic factors associated with the syndrome, the
immunopathogenesis remains incompletely deﬁned, and no
diagnostic test exists [9]. Thus far, explorations of the immune
response in TB-IRIS pathogenesis have been of those measured
in blood, which is likely an incomplete representation of the
immune response in affected tissue—for example, the central
nervous system (CNS).
In this study, we investigated inﬂammatory mediators in ce-
rebrospinal ﬂuid (CSF; 40 mediators) and blood (33 mediators)
from human immunodeﬁciency virus (HIV)–infected patients
with tuberculous meningitis (TBM) who started ART during
tuberculosis treatment. We compared serial ﬁndings between
patients who did and those who did not develop paradoxical
TBM-IRIS. The clinical ﬁndings of this cohort were described




We conducted a prospective, observational study at a public sec-
tor hospital in Cape Town, South Africa, recruiting ART-naive
HIV-infected adults who presented with TBM during a 20-
month period. The details of the clinical methods have been
published elsewhere [3]. Both TBM and paradoxical TBM-
IRIS were diagnosed according to published case deﬁnitions
[4, 10]; ART-naive HIV-infected patients without meningitis
who presented with symptoms and/or signs necessitating a
lumbar puncture were enrolled as control participants. The
University of Cape Town Human Research Ethics Committee
approved the study, and written informed consent was obtained
from all patients or their relatives (Supplementary Data).
Procedure
Paired CSF and blood samples were collected from patients with
TBM at 3–5 time points, shown in Figure 1. Samples were col-
lected at 1 time point from control participants. Samples were
stored at −80°C and analyzed in batches as detailed below. The
primary outcome measure was CSF mediator concentrations, at
the time of TBM-IRIS presentation in patients who developed
TBM-IRIS and 2 weeks after ART initiation in those who did
not. The 2 weeks after ART initiation time point in patients
with TBM without IRIS (TBM-non-IRIS) was based on the me-
dian time (14 days after ART initiation) reported for TB-IRIS
development [4]. Secondary analyses included comparisons of
CSF and blood ﬁndings between (1) the combined TBM group
and controls, (2) patients with TBM-IRIS and TBM-non-IRIS
at TBM diagnosis and ART initiation, and (3) time points with-
in TBM-IRIS and TBM-non-IRIS groups.
Luminex Multiplex and Enzyme-Linked Immunosorbent Assays
Mediators analyzed in CSF and serum samples with Luminex
multiplex assays included tumor necrosis factor (TNF), interfer-
on (IFN)-γ, interleukin (IL)-2, interleukin 4, interleukin 10,
interleukin 13, interleukin 1β, interleukin 6 (IL-6), interleukin
12p40 (IL-12p40), interleukin 17 (IL-17), IFN-α2, CC chemo-
kine ligand (CCL) 2, CCL3, CCL4, CXC chemokine ligand
(CXCL) 1–3, CXCL8, granulocyte colony-stimulating factor
(G-CSF) and granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF). Matrix metalloproteinase (MMP) 1, 2, 3, 7, 9,
10, 12, and 13, and tissue inhibitors of MMP (TIMP) 1 and 2
were analyzed with Luminex multiplex assays in CSF and plas-
ma. Mediators measured with enzyme-linked immunosorbent
assays in CSF and serum samples included IL-12p70, interleu-
kin 17A (IL-17A), interleukin 21, 22, and 23, and CXCL10.
Figure 1. Flow diagram of time points when lumbar puncture and phle-
botomy were performed in patients with tuberculous meningitis (TBM).
Drug interventions are indicated at each time point (gray boxes). Proce-
dures were performed at a minimum of 3 time points: (1) TBM diagnosis,
(2) antiretroviral treatment (ART) initiation, and (3) 2 weeks after ART ini-
tiation or TBM immune reconstitution inﬂammatory syndrome (IRIS) presen-
tation, whichever occurred ﬁrst. Patients in whom TBM-IRIS developed later
than 2 weeks after ART initiation underwent repeated procedures at TBM-
IRIS presentation. Unless lumbar puncture was contraindicated, procedures
were repeated in patients with TBM-IRIS 2 weeks after TBM-IRIS presen-
tation. At the start of the study, the ﬁrst-line ART regimen for patients re-
ceiving tuberculosis treatment in South Africa was stavudine, lamivudine,
and efavirenz (started in 10 patients [63%] with TBM-IRIS and 10 [56%]
with TBM without IRIS [TBM-non-IRIS]). Later during the study, tenofovir
replaced stavudine, according to revised national guidelines (started in 4
patients [25%] with TBM-IRIS and 5 [28%] with TBM-non-IRIS). Five pa-
tients (2 [13%] with TBM-IRIS and 3 [17%] with TBM-non-IRIS), in whom
these regimens were contraindicated, received zidovudine, lamivudine, and
efavirenz.
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The CSF samples were also analyzed with enzyme-linked im-
munosorbent assays for interleukin 18 (IL-18) and neutro-
phil-associated mediators: cathepsin G, lipocalin 2, LL-37,
human neutrophil peptides 1–3, complement 5a (C5a), and
S100A8/A9 (Supplementary Data).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism (ver-
sion 5; GraphPad) and R (version 3.0) software [11]. We com-
pared variables between groups using Wilcoxon rank sum tests.
Within groups, we compared variables between time points
and between blood and CSF compartments, using Wilcoxon
matched-pairs tests. Correlations were estimated using the
Kendall τ coefﬁcient. We performed unsupervised agglomerative
hierarchical clustering on mediators in CSF samples, using com-
plete linkage and Euclidean distance measures. We assessed clus-
ter-wise stability with 2 resampling schemes (bootstrap and
subsetting; 100 resampling runs), and we computed the Jaccard
similarities [12, 13]. Throughout the analyses, we used an unad-
justed P value <.05 as a nominal threshold for statistical signiﬁ-
cance, except for the correlation analysis, which provides P values
adjusted for the false discovery rate (Benjamini and Hochberg)
[14]. Owing to the large number of statistical tests, our P values
should be used for guidance in interpretation rather than ﬁnality
(see Supplementary Data for details on multivariate analysis).
RESULTS
Demographic and Clinical Results
The demographic characteristics and baseline blood results of
patients with TBM (n = 34) and controls (n = 14) are presented
in Table 1. Sixteen patients with TBM developed TBM-IRIS, a
median of 14 days (IQR, 4–20 days) after starting ART, and 18
did not [3]. Of note, 15 of 16 patients with TBM-IRIS and 6 of
18 with TBM-non-IRIS had M. tuberculosis cultured from CSF
samples at TBM diagnosis (P < .001). There were no signiﬁcant
differences in CD4 cell counts and plasma HIV loads between
patients with TBM and controls (Table 1). The CD4 counts and
plasma and CSF HIV loads were reported elsewhere for these
TBM-IRIS and TBM-non-IRIS groups and did not differ signif-
icantly between groups either at baseline or during follow-up [3].
CSF Mediator Concentrations in Patients With TBM and Controls
Interleukin 2, 4, 13, 21, and 23, IL-12p70, MMP-12, and MMP-
13 were excluded from all analyses because of minimal or no
detection in CSF and blood samples (Supplementary Data).
Compared with controls with no meningitis at presentation,
patients with TBM had signiﬁcantly higher (P < .05) CSF con-
centrations of 28 of 32 mediators; only CCL2 and IL-17 levels
were similar, and IL-18 and C5a had medians equal to 0 in both
groups (Supplementary Table 2). Conversely, concentrations of
only 6 of 25 mediators in blood differed between groups; IFN-γ,
IL-6, CXCL8, CXCL10, and MMP-3 concentrations were higher
(P < .05), and CCL2 concentrations were lower (P = .045) in
patients with TBM.
Highly Compartmentalized Inﬂammatory Responses
in TBM With or Without IRIS Development
Within the TBM group at the time of TBM diagnosis, cytokine
and chemokine concentrations were signiﬁcantly higher in CSF
than in blood samples, with the exception of IL-12p40, which
showed comparable levels in blood and CSF, and CXCL1-3,
which showed a higher trend (P = .06) in blood (Supplemen-
tary Table 2). Conversely, levels of MMP-1–3, MMP-7, and
MMP-10 were signiﬁcantly higher in blood than in CSF sam-
ples, and only MMP-9 and its inhibitor TIMP-1 were increased
in CSF relative to blood (P < .001). Within the control group,
blood cytokine, chemokine, MMP, and TIMP concentrations
were either similar to or higher than CSF concentrations, with
Table 1. Baseline Characteristics of Patients Presenting With









Age, y 33 (28–44) 34 (27–38) .95
Female, No. (%) 15 (44) 9 (64) .34
Body mass index 20.0 (18.3–22.7) 20.5 (19.9–27.3) .17
Blood values
Sodium, mmol/L 129 (123–131) 135 (133–137) <.001
Hemoglobin, g/dL 11.4 (8.8–13.1) 12.4 (10.8–13.4) .10
C-reactive protein,
mg/L
40 (6–78) 5 (1–8) .005
CD4 count, cells/µL 113 (69–199) 129 (75–180) .91




177 (87–339) 6 (2–13) <.001
Neutrophil count,
×106/L
20 (2–42) 0 (0–0) <.001
Protein, g/L 1.94 (1.29–3.06) 0.51 (0.38–0.87) <.001
Glucose, CSF/blood
ratio
0.30 (0.17–0.5) 0.53 (0.5–0.74) <.001
Abbreviations: CSF, cerebrospinal fluid; HIV, human immunodeficiency virus;
IQR, interquartile range; TBM, tuberculous meningitis.
a Values represent medians (IQRs) unless otherwise specified.
b P values were calculated for comparisons between groups, using the
Wilcoxon rank sum test for continuous variables and the Fisher exact test for
categorical variables. Differences were considered statistically significant at
P < .05.
c Diagnoses in controls included HIV-associated psychosis (n = 4), tension
headache (n = 4), generalized tonic-clonic seizures (n = 2), meningioma
(n = 1), stroke (n = 1), depression (n = 1), and HIV-associated neurocognitive
disorder (n = 1).
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the exceptions of G-CSF, IFN-α2, CCL2, CCL3, and CXCL8
concentrations, which were higher in CSF. Consistent with
the combined TBM group, a highly compartmentalized inﬂam-
matory response was seen in both subgroups when the TBM
group was divided into those who did and those who did not
subsequently develop TBM-IRIS (Figure 2, Supplementary
Figure 1, and Supplementary Tables 3–5).
CSF Mediator Concentrations and Dynamic Changes Over Time
in TBM-IRIS Compared With TBM-Non-IRIS
At the time of TBM diagnosis, patients who subsequently devel-
oped TBM-IRIS, compared with those who did not, showed
signiﬁcantly increased CSF T-helper 1 cells (IFN-γ and IL-18)
and other proinﬂammatory cytokines (TNF, IL-6, interleukin 1β,
G-CSF, and GM-CSF), IFN-α2, chemokines (CCL2–4, CXCL1-3,
CXCL8, and CXCL 10), neutrophil-associated mediators (human
neutrophil peptides 1–3, lipocalin 2, C5a, and S100A8/A9),
MMP-1, MMP-7, MMP-10, TIMP-1 and TIMP-2 (Figure 2
and Supplementary Table 3). Figure 3 and Supplementary
Table 6 show the changes in CSF mediator concentrations
over time for patients with TBM-IRIS or TBM-non-IRIS. In
both groups there was a signiﬁcant decrease in most mediators
tested in CSF during tuberculosis treatment before initiation of
ART. However, IL-12p40 and IL-17A showed a signiﬁcant
Figure 2. Box plots of mediator concentrations over time in cerebrospinal ﬂuid of patients who developed tuberculous meningitis (TBM) immune recon-
stitution inﬂammatory syndrome (IRIS) (red) and those who did not (blue). The assay limits of detection have been substituted for 0 values. The left y-axis is
a log10 scale, and the right y-axis indicates time points of sample collection. Within graphs, boxes with horizontal lines represent interquartile ranges (IQR)
and medians, and vertical line represent 95% conﬁdence intervals. Data points for outliers (≥1.5 × IQR) are included. (See Supplementary Tables 3–5 for P
values of analyses between groups.) For patients with TBM-IRIS, the “2 wk after antiretroviral therapy (ART)” time point indicates ﬁndings at TBM-IRIS
presentation, which occurred a median of 14 days (interquartile range, 4–20 days) after initiation of ART. Concentrations of all mediators were measured as
picograms per milliliter, with the exception of cathepsin G, which was measured in units per milliliter. Abbreviations: C5a, complement 5a; CCL, CC che-
mokine ligand; CXCL, CXC chemokine ligand; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor;
HNP, human neutrophil peptide; IFN, interferon; IL, interleukin; MMP, metalloproteinase; TIMP, tissue inhibitor of MMP; TNF, tumor necrosis factor.
4 • CID • HIV/AIDS







increase from baseline in patients with TBM-IRIS, but not those
with TBM-non-IRIS, before initiation of ART.
At TBM-IRIS presentation (compared with 2 weeks after
ART initiation in patients with TBM-non-IRIS), patients with
TBM-IRIS showed signiﬁcantly higher CSF concentrations for
almost all mediators (31 of 32), except IFN-α2 (Figure 2 and
Supplementary Table 5). Antiretroviral therapy was associated
with marked rises in CSF inﬂammatory mediator concentra-
tions in patients with TBM-IRIS, despite adjunctive corticoste-
roid therapy (13 of 16 patients were still receiving prednisone),
such that concentrations reached similar or higher levels at
TBM-IRIS presentation, approximately 2 weeks after ART
Figure 3. Representative examples of changes over time of cerebrospinal ﬂuid (CSF) mediators in patients who developed tuberculous meningitis (TBM)
immune reconstitution inﬂammatory syndrome (IRIS) (n = 16) (red) and those who did not (n = 18) (blue). For patients with TBM-IRIS, the “2 wk after ART
[antiretroviral therapy]” time point indicates ﬁndings at TBM-IRIS presentation. Some patients with TBM without IRIS (TBM-non-IRIS) showed an increase in
mediator concentration and the ratio of metalloproteinase (MMP) 9 to tissue inhibitor of MMP tissue inhibitor of MMP (TIMP) 1 after starting ART; these
patients had CSF cultures positive for Mycobacterium tuberculosis at TBM diagnosis. Abbreviations: CXCL, CXC chemokine ligand; HNP, human neutrophil
peptide; IL, interleukin; TNF, tumor necrosis factor.
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initiation, compared with those at TBM presentation (Supple-
mentary Table 6A). Conversely, in TBM-non-IRIS no signiﬁ-
cant CSF changes were observed between the start of ART
and 2 weeks thereafter (Supplementary Table 6B). Moreover,
comparing ﬁndings between samples taken 2 weeks after start-
ing ART to those from TBM diagnosis in TBM-non-IRIS, a sig-
niﬁcant decrease was noted in CSF concentrations of G-CSF,
GM-CSF, CCL3, CCL4, TNF, IFN-γ, IL-6, CXCL8, CXCL10,
lipocalin 2, S100A8/A9, MMP-10, and TIMP-1. This suggests
that the rise in CSF mediators observed in TBM-IRIS 2 weeks
after ART reﬂected IRIS development, not simply the effects of
ART prescription.
Samples taken 2 weeks after TBM-IRIS presentation were
available for analysis in 10 of 16 patients with TBM-IRIS;
death (n = 1) or contraindications to lumbar puncture (n = 5)
precluded CSF sampling in the others. Compared with mediator
concentrations at TBM-IRIS presentation (when prednisone
was restarted or the dose increased), the only signiﬁcant chang-
es in CSF mediators were decreased concentrations of G-CSF
(P = .04) and LL-37 (P = .02), 2 weeks after TBM-IRIS.
Modest Between-Group Differences in Blood Compared
With CSF Samples
At TBM diagnosis, blood concentrations were similar between
TBM-IRIS and TBM-non-IRIS with the exception of IFN-α2
(P = .03), CXCL8 (P = .005), and MMP-1 (P = .04) concentra-
tions, which were higher in patients with TBM-IRIS (Supple-
mentary Figure 1 and Supplementary Table 3). The CXCL8
concentration remained elevated in TBM-IRIS at the start of
ART (P = .02; Supplementary Figure 1 and Supplementary
Table 4). Two weeks after the start of ART, concentrations of
TNF, IFN-γ, CCL4, and MMP-7 (.01 <P <.05 for all) and
CXCL8 and CXCL10 (.001 <P <.01 for both) were elevated in
blood samples from the TBM-IRIS group compared with the
TBM-non-IRIS group, and TIMP-2 was higher in the TBM-
non-IRIS group (P = .046; Supplementary Figure 1 and Supple-
mentary Table 5).
CSF Neutrophil Counts and S100A8/A9 in Patients With TBM-IRIS
and Culture-Positive Patients With TBM-Non-IRIS
Unsupervised hierarchical clustering of patients with TBM
by CSF mediators showed that patients with TBM-non-IRIS
whose CSF cultures were positive forM. tuberculosis at TBM di-
agnosis tended to cluster at all time points with patients with
TBM-IRIS (Figure 4 and Supplementary Table 7). Patients
with TBM-non-IRIS who were culture positive showed media-
tor proﬁles more similar to patients with TBM-IRIS than to cul-
ture-negative patients with TBM-non-IRIS, at TBM diagnosis
(Supplementary Table 8) and some of these patients also had
increasing concentrations of mediators after starting ART as
shown in Figure 3. Supplementary Table 9 shows the
similarities between CSF ﬁndings in culture-positive patients
with TBM-non-IRIS and those with TBM-IRIS and the differ-
ences between culture-positive and culture-negative patients
with TBM-non-IRIS, 2 weeks after starting ART. Neutrophil
counts and S100A8/A9 distinguished culture-positive patients
with TBM-non-IRIS from patients with TBM-IRIS; neutrophils
differentiated them at baseline (median [IQR], 3 [0–14] vs 38
[11–117] cells × 106/L; P = .02) and 2 weeks after ART initiation
(2 [0–11] vs 52 [17–244] cells × 106/L; P = .003), and S100A8/
A9 differentiated them 2 weeks after ART (15 346 [0–19 152]
vs 33 500 [27 000–48 000] pg/mL; P = .001). Correlation analyses
showed no biologically signiﬁcant correlations between neutro-
phil and lymphocyte counts and mediator concentrations in
CSF samples from patients with TBM-IRIS or TBM-non-IRIS
over time (Supplementary Data).
DISCUSSION
To our knowledge, this is the only comprehensive analysis to
date of serial CSF and blood immune mediators in TBM-
IRIS. Neutrophils, lymphocytes, and total protein concentra-
tions [3], as well as all analyzed mediators (except IFN-α2),
were elevated in patients with TBM-IRIS 2 weeks after ART ini-
tiation, compared with patients with TBM-non-IRIS. This
widespread up-regulation of diverse mediators of diverse cellu-
lar functions suggests that both innate and adaptive immune re-
sponses are involved in TBM-IRIS pathogenesis.
Adjunctive corticosteroid treatment is associated with
reduced short-term mortality in HIV-uninfected patients with
TBM [15] and with symptomatic improvement in TB-IRIS [1].
In our study, increased CSF inﬂammation was observed after
ART initiation in patients with TBM-IRIS despite corticosteroid
therapy. Furthermore, a decrease of only 2 mediators was ob-
served 2 weeks after corticosteroids were increased in dosage
or restarted at TBM-IRIS presentation. Previous studies in pa-
tients with TBM also found little effect of corticosteroids on
CSF cytokine or chemokine concentrations [16]. The CSF con-
centrations of MMP-9 were shown to decrease in patients re-
ceiving dexamethasone compared with controls early during
TBM treatment, and it was postulated that this may represent
a mechanism by which corticosteroids improve outcome in
these patients [17]. However, in our study MMP-9 concentra-
tions did not change after initiation of tuberculosis treatment
(plus corticosteroids) in patients with either TBM-IRIS or
TBM-non-IRIS, and they increased signiﬁcantly after ART ini-
tiation in the TBM-IRIS group. These ﬁndings suggest that im-
munomodulatory treatment options more potent and speciﬁc
than corticosteroids need to be explored for the prevention
and/or management of TBM-IRIS.
As reported elsewhere for extrapulmonary tuberculosis, in-
cluding TBM [18], pleural [19], and pericardial tuberculosis
6 • CID • HIV/AIDS







Figure 4. Unsupervised hierarchical clustering of tuberculous meningitis (TBM) at TBM diagnosis (A), initiation of antiretroviral therapy (ART) (B), and TBM
immune reconstitution inﬂammatory syndrome (IRIS) presentation or 2 weeks after ART initiation (patients with non-TBM-IRIS) (C). IRIS status indicates
patients who developed TBM-IRIS (red) and those who did not (blue). Culture status indicates cerebrospinal ﬂuid cultures positive (black) or negative (green)
for Mycobacterium tuberculosis at TBM diagnosis. Values plotted are natural log + 1. Corresponding concentrations in picograms per milliliter are indicated
on the color key. Concentrations of all mediators were measured in picograms per milliliter, with the exception of cathepsin G, measured in units per milliliter;
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[20], a highly compartmentalized inﬂammatory response in CSF
was seen in patients with TBM. Relatively fewer differences be-
tween TBM-IRIS and TBM-non-IRIS groups were observed for
mediators in blood compared with the differences observed in
CSF. Corticosteroids do modulate blood inﬂammatory responses
in persons coinfected with tuberculosis and HIV persons [21, 22]
and probably further attenuated differences between TBM-IRIS
and TBM-non-IRIS groups after TBM presentation after the
start of tuberculosis treatment and corticosteroids.
High baseline CSF mycobacterial load (reﬂected by M. tuber-
culosis culture positivity) is a risk factor for subsequent TBM-
IRIS in patients with TBM [3]. This is similar to ﬁndings in
cryptococcal meningitis (CM) IRIS, wherein high CSF fungal
loads (reﬂected by quantitative culture) at CM diagnosis also pre-
dict subsequent IRIS [23]. Findings of previous studies suggested
that, unlike the highly inﬂammatory baseline presentation being
predictive of TBM-IRIS, paradoxical CM-IRIS is predicted by a
paucity of inﬂammation at CM diagnosis, as evidenced by a
lack of CSF leukocytes and/or normal protein level [23, 24] and
lower CSF concentrations of cytokines and chemokines (ie, IL-6,
interleukin 8, TNF, and IFN-γ) [24]. These differing ﬁndings in
TBM and CM suggest that more than one pathogenic mecha-
nism underlies neurological forms of IRIS. More recent studies
in CM-IRIS have demonstrated a chemokine proﬁle before
ART in CSF that predicts subsequent IRIS risk, including higher
CCL2/CXCL10 and CCL3/CXCL10 ratios [25]. Furthermore, in
the same cohort of patients with CM, markers of activation and/
or function expressed by natural killer cells and monocytes were
compartmentalized in the CNS relative to blood before ART ini-
tiation, supporting a role for the innate immune system at the dis-
ease site in CM pathogenesis [26].
In this study, patients with TBM-non-IRIS whose CSF cul-
tures were positive for M. tuberculosis at TBM diagnosis tended
to have higher baseline mediator concentrations than culture-
negative patients with TBM-non-IRIS and showed recurrent in-
ﬂammation after ART initiation, reaching levels of magnitude
comparable to those in TBM-IRIS 2 weeks after ART initiation.
These increases in mediator concentrations were not seen in
culture-negative patients with TBM-non-IRIS. Drug regimens
in TBM are based on the same principles as pulmonary tuber-
culosis, rather than being informed by results of randomized
controlled trials in TBM [27]. Our data support research into
antimicrobial regimens containing higher-than-normal-dose
rifampicin as well as a ﬂuoroquinolone [28, 29]. Given that my-
cobacterial load drives inﬂammation during ART, improving
early mycobacterial clearance from the CNS by using a more
potent TBM drug regimen in HIV-infected patients with
TBM may decrease the risk of TBM-IRIS.
Figure 4 continued. neutrophils and lymphocytes were measured as cells × 106 per liter. Abbreviations: C5a, complement 5a; CCL, CC chemokine ligand;
CXCL, CXC chemokine ligand; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HNP, human neutrophil
peptide; IFN, interferon; IL, interleukin; MMP, metalloproteinase; TIMP, tissue inhibitor of MMP; TNF, tumor necrosis factor.
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Although initial studies explored the role of lymphocytes
in TB-IRIS pathogenesis, increasing evidence implicates the in-
nate immune system as an important contributor [9], and it is
proposed that neutrophils mediate the pathology in tuberculosis
[30].Based on these results and the association we found between
CSF neutrophils and TBM-IRIS [3], we investigated neutrophil-
associated mediators in the CSF of our cohort. All measured neu-
trophil-associated mediators were increased 2 weeks after initia-
tion of ART in the TBM-IRIS compared with the TBM-non-IRIS
group. Unlike the other neutrophil-associated mediators but sim-
ilar to neutrophils, S100A8/A9 was also increased in patients with
TBM-IRIS compared with those with TBM-non-IRIS with base-
line CSF M. tuberculosis culture positivity 2 weeks after ART ini-
tiation, when TBM-IRIS usually presents. Given these ﬁndings,
we hypothesize that S100A8/A9 contributes to the recurrent
CSF inﬂammation that manifests as clinical deterioration in pa-
tients with TBM-IRIS. S100A8/A9 is a protein complex that
seems to have prominent immune regulatory properties, such
as neutrophil chemoattraction and stimulation [31]. Several stud-
ies have shown that serum S100A8/A9 concentrations are
increased in HIV-uninfected patients with pulmonary tuber-
culosis compared with controls, and that they are correlated
with radiographic severity [32, 33]. In a murine model of tuber-
culosis, IL-17–induced S100A8/A9 was a key factor in neutrophil
accumulation and exacerbated lung inﬂammation by inducing
proinﬂammatory cytokines [33]. Given that IL-17 may therefore
be important in TBM-IRIS pathogenesis, but considering the low
concentrations previously found in vivo in patients with tubercu-
losis [20, 34], we measured IL-17A with a high-sensitivity assay.
The CSF IL-17A concentrations increased signiﬁcantly over
time in patients with TBM-IRIS, reaching concentrations more
than 8-fold that of TBM diagnosis at TBM-IRIS presentation,
whereas the opposite trend occurred in patients with TBM-
non-IRIS. These ﬁndings support previous suggestions that IL-
17 may be important in TB-IRIS pathogenesis [34].
Although this is the ﬁrst comprehensive analysis hitherto of
the disease site coupled with blood immune mediators in TB-
IRIS, we acknowledge certain limitations. We did not include
HIV-uninfected patients with TBM as controls, and we exclud-
ed patients with neurological deterioration before ART initia-
tion. We were therefore unable to compare the inﬂammatory
response in TBM-IRIS to that of the “paradoxical reaction”
characterized by neurological deterioration, which can occur
in both HIV-infected and HIV-uninfected patients with TBM
after the start of tuberculosis treatment [35]. This is a descrip-
tive study of mediators in patients with TBM; cellular contribu-
tions to mediator production in CSF and blood were not
determined by functional experiments.
Our ﬁndings have several important implications. First, oral
corticosteroid therapy during TBM treatment is insufﬁcient to
prevent, or rapidly reduce, the inﬂammatory response that
characterizes TBM-IRIS; in addition to investigations through
randomized trials of different corticosteroid doses and routes
of administration in the management of TBM-IRIS , alternative
immunomodulatory therapies should be explored for the pre-
vention and treatment of the disease. Second, although the
adaptive immune system seems to be activated in TBM-IRIS,
the sequence of immunological events in the CNS suggests a
major contribution of the innate response in this condition. Ce-
rebrospinal ﬂuid neutrophils, which may be driven through an
IL-17– and S100A8/A9-dependent pathway, are associated with
the most severe CNS inﬂammation manifesting as TBM-IRIS;
these ﬁndings are likely to direct future research into TB-IRIS
immunopathogenesis and management strategies.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org). Supplementary materials consist of data pro-
vided by the author that are published to beneﬁt the reader. The posted ma-
terials are not copyedited. The contents of all supplementary data are the
sole responsibility of the authors. Questions or messages regarding errors
should be addressed to the author.
Notes
Acknowledgments. We thank the patients who participated in the study
and Monica Magwayi for providing care to patients during the study. We are
grateful to the clinical and administrative staff of the provincial government
of the Western Cape Department of Health for their support of this study.
Disclaimer. The content of this article is solely the responsibility of the
authors and does not necessarily represent the ofﬁcial views of the sponsors.
The sponsors further had no role in study design; data collection, analysis
and interpretation; writing of the manuscript or decision to submit for pub-
lication; they accept no liability whatsoever in this regard.
Financial support. This work was supported by the Carnegie Corpora-
tion Training Award and Discovery Foundation Academic Fellowship
Award (S. M.); the Perinatal HIV Research Unit, the US Agency for Inter-
national Development, and the President’s Emergency Plan for AIDS Relief
(S. M., D. J. P., and C. S.); the Wellcome Trust (grants WT 097254, 084323,
098316 and 088316 to S. M., G. M., and R. J. W.); National Institutes of
Health and Fogarty International Center South Africa TB/AIDS training
awards (grants NIH/FIC U2RTW007373-01A, U2RTW007370-01A1, and
U2RTW007373 ICORTA to G. M., D. J. P., and C. S., respectively); the Na-
tional Research Foundation of South Africa (grant UID 85858 to G. M.); and
the Medical Research Council (UK) (grant U.1175.02.002.00014.01 to
R. J. W.).
Potential conﬂicts of interest. All authors: No potential conﬂicts of
interest.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-
controlled trial of prednisone for paradoxical tuberculosis-associated
immune reconstitution inﬂammatory syndrome. AIDS 2010; 24:
2381–90.
2. BurmanW, Weis S, Vernon A, et al. Frequency, severity and duration of
immune reconstitution events in HIV-related tuberculosis. Int J Tuberc
Lung Dis 2007; 11:1282–9.
HIV/AIDS • CID • 9







3. Marais S, Meintjes G, Pepper DJ, et al. Frequency, severity, and predic-
tion of tuberculous meningitis immune reconstitution inﬂammatory
syndrome. Clin Infect Dis 2013; 56:450–60.
4. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune
reconstitution inﬂammatory syndrome: case deﬁnitions for use in re-
source-limited settings. Lancet Infect Dis 2008; 8:516–23.
5. Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of
paradoxical tuberculosis-associated immune reconstitution inﬂamma-
tory syndrome: a case series. Clin Infect Dis 2009; 48:e96–107.
6. Agarwal U, Kumar A, Behera D, French MA, Price P. Tuberculosis as-
sociated immune reconstitution inﬂammatory syndrome in patients in-
fected with HIV: meningitis a potentially life threatening manifestation.
AIDS Res Ther 2012; 9:17.
7. Narendran G, Andrade BB, Porter BO, et al. Paradoxical tuberculosis
immune reconstitution inﬂammatory syndrome (TB-IRIS) in HIV pa-
tients with culture conﬁrmed pulmonary tuberculosis in India and the
potential role of IL-6 in prediction. PLoS One 2013; 8:e63541.
8. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Im-
mune reconstitution inﬂammatory syndrome in patients starting antire-
troviral therapy for HIV infection: a systematic review and meta-
analysis. Lancet Infect Dis 2010; 10:251–61.
9. Lai RP, Nakiwala JK, Meintjes G, Wilkinson RJ. The immunopathogen-
esis of the HIV tuberculosis immune reconstitution inﬂammatory syn-
drome. Eur J Immunol 2013; 43:1995–2002.
10. Bhigjee AI, Padayachee R, Paruk H, Hallwirth-Pillay KD, Marais S,
Connoly C. Diagnosis of tuberculous meningitis: clinical and laboratory
parameters. Int J Infect Dis 2007; 11:348–54.
11. R Core Team (2013). R: A language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna, Austria.
Available at: http://www.R-project.org. Accessed 21 January 2014.
12. Hennig C. Cluster-wise assessment of cluster stability. Comput Stat
Data Anal 2007; 52:258–71.
13. Hennig C. Dissolution point and isolation robustness: robustness
criteria for general cluster analysis methods. J Multivar Anal 2008;
99:1154–76.
14. Hochberg YBY. Controlling the false discovery rate: a practical and
powerful approach to multiple testing. J R Stat Soc Series B 1995;
57:289–300.
15. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the
treatment of tuberculous meningitis in adolescents and adults. N Engl
J Med 2004; 351:1741–51.
16. Simmons CP, Thwaites GE, Quyen NT, et al. The clinical beneﬁt of ad-
junctive dexamethasone in tuberculous meningitis is not associated
with measurable attenuation of peripheral or local immune responses.
J Immunol 2005; 175:579–90.
17. Green JA, Tran CT, Farrar JJ, et al. Dexamethasone, cerebrospinal ﬂuid
matrix metalloproteinase concentrations and clinical outcomes in tu-
berculous meningitis. PLoS One 2009; 4:e7277.
18. Thwaites GE, Simmons CP, Than Ha Quyen N, et al. Pathophysiology
and prognosis in Vietnamese adults with tuberculous meningitis. J Infect
Dis 2003; 188:1105–15.
19. Wilkinson KA, Wilkinson RJ, Pathan A, et al. Ex vivo characterization
of early secretory antigenic target 6–speciﬁc T cells at sites of active dis-
ease in pleural tuberculosis. Clin Infect Dis 2005; 40:184–7.
20. Matthews K, Wilkinson KA, Kalsdorf B, et al. Predominance of inter-
leukin-22 over interleukin-17 at the site of disease in human tuberculo-
sis. Tuberculosis 2011; 91:587–93.
21. Conesa-Botella A, Meintjes G, Coussens AK, et al. Corticosteroid
therapy, vitamin D status, and inﬂammatory cytokine proﬁle in the
HIV-tuberculosis immune reconstitution inﬂammatory syndrome.
Clin Infect Dis 2012; 55:1004–11.
22. Meintjes G, Skolimowska KH, Wilkinson KA, et al. Corticosteroid-
modulated immune activation in the tuberculosis immune reconstitu-
tion inﬂammatory syndrome. Am J Respir Crit Care Med 2012;
186:369–77.
23. Chang CC, Dorasamy AA, Gosnell BI, et al. Clinical and mycological
predictors of cryptococcosis-associated immune reconstitution inﬂam-
matory syndrome (C-IRIS). AIDS 2013; 27:2089–99.
24. Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospi-
nal ﬂuid inﬂammation in cryptococcal meningitis is associated with
subsequent immune reconstitution inﬂammatory syndrome. J Infect
Dis 2010; 202:962–70.
25. Chang CC, Omarjee S, Lim A, et al. Chemokine levels and chemokine
receptor expression in the blood and the cerebrospinal ﬂuid of HIV-
infected patients with cryptococcal meningitis and cryptococcosis-
associated immune reconstitution inﬂammatory syndrome. J Infect
Dis 2013; 208:1604–12.
26. Naranbhai V, Chang CC, Durgiah R, et al. Compartmentalization of in-
nate immune responses in the central nervous system during cryptococ-
cal meningitis/HIV coinfection. AIDS 2014; 28:657–66.
27. Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more
questions, still too few answers. Lancet Neurol 2013; 12:999–1010.
28. Ruslami R, Ganiem AR, Dian S, et al. Intensiﬁed regimen containing
rifampicin and moxiﬂoxacin for tuberculous meningitis: an open-
label, randomised controlled phase 2 trial. Lancet Infect Dis 2013;
13:27–35.
29. Heemskerk D, Day J, Chau TT, et al. Intensiﬁed treatment with high
dose rifampicin and levoﬂoxacin compared to standard treatment for
adult patients with tuberculous meningitis (TBM-IT): protocol for a
randomized controlled trial. Trials 2011; 12:25.
30. Lowe DM, Redford PS, Wilkinson RJ, O’Garra A, Martineau AR.
Neutrophils in tuberculosis: friend or foe?. Trends Immunol 2012;
33:14–25.
31. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinﬂamma-
tory activities of S100: proteins S100A8, S100A9, and S100A8/A9
induce neutrophil chemotaxis and adhesion. J Immunol 2003; 170:
3233–42.
32. Pechkovsky DV, Zalutskaya OM, Ivanov GI, Misuno NI. Calprotectin
(MRP8/14 protein complex) release during mycobacterial infection in
vitro and in vivo. FEMS Immunol Med Microbiol 2000; 29:27–33.
33. Gopal R, Monin L, Torres D, et al. S100A8/A9 proteins mediate neutro-
philic inﬂammation and lung pathology during tuberculosis. Am J
Respir Crit Care Med 2013; 188:1137–46.
34. Tadokera R, Meintjes G, Skolimowska KH, et al. Hypercytokinaemia
accompanies HIV-tuberculosis immune reconstitution inﬂammatory
syndrome. Eur Respir J 2011; 37:1248–59.
35. Sutlas PN, Unal A, Forta H, Senol S, Kirbas D. Tuberculous meningitis
in adults: review of 61 cases. Infection 2003; 31:387–91.
10 • CID • HIV/AIDS
 by guest on O
ctober 4, 2014
http://cid.oxfordjournals.org/
D
ow
nloaded from
 
